These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 2314822)
1. Cisplatin-containing versus cisplatin-free adjuvant chemotherapy in ovarian carcinoma. Results after second-look laparotomy. Schneider J; Martin M; Erasun F; Matia JC; Rodriguez-Escudero FJ Oncology; 1990; 47(2):109-11. PubMed ID: 2314822 [TBL] [Abstract][Full Text] [Related]
2. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679 [TBL] [Abstract][Full Text] [Related]
3. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. Wadler S; Yeap B; Vogl S; Carbone P Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766 [TBL] [Abstract][Full Text] [Related]
4. Cisplatin and cyclophosphamide in early epithelial ovarian carcinoma. Chiara S; Conte PF; Bruzzone M; Falcone A; Sertoli MR; Carnino F; Mossetti C; Iura R; Durando C; Guercio E Chemioterapia; 1987 Oct; 6(5):380-3. PubMed ID: 3427698 [TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal cisplatin chemotherapy versus abdominopelvic irradiation in ovarian carcinoma patients after second-look laparotomy. Menczer J; Ben-Baruch G; Modan M; Brenner H Cancer; 1989 Apr; 63(8):1509-13. PubMed ID: 2924259 [TBL] [Abstract][Full Text] [Related]
6. Phase II trial of ifosfamide and cisplatinum in advanced ovarian cancer. Aziz Z; Zahid M; Ud Din Ahmed Z; Arshad T Aust N Z J Med; 1998 Jun; 28(3):403-9. PubMed ID: 9673759 [TBL] [Abstract][Full Text] [Related]
7. The role of second-look laparotomy in the management of patients with stage II, III and IV ovarian cancers following chemotherapy with cisplatin, adriamycin and cyclophosphamide. Kirwan PH; Naftalin NJ; Khanna S; Aukett RJ Br J Obstet Gynaecol; 1986 Jun; 93(6):629-33. PubMed ID: 3730331 [TBL] [Abstract][Full Text] [Related]
8. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501 [TBL] [Abstract][Full Text] [Related]
9. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma. Barlow JJ; Lele SB Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408 [TBL] [Abstract][Full Text] [Related]
10. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811 [TBL] [Abstract][Full Text] [Related]
11. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy. Bolis G; Villa A; Guarnerio P; Ferraris C; Gavoni N; Giardina G; Melpignano M; Scarfone G; Zanaboni F; Parazzini F Cancer; 1996 Jan; 77(1):128-31. PubMed ID: 8630918 [TBL] [Abstract][Full Text] [Related]
12. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Thigpen T; Vance R; Puneky L; Khansur T Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816 [TBL] [Abstract][Full Text] [Related]
13. Survival with intraperitoneal cisplatin in advanced ovarian cancer after second-look laparotomy. de Gramont A; Demuynck B; Louvet C; Gonzalez-Canali G; Varette C; Pigné A; Marpeau L; Herbulot P; Lagadec B; Cady J Am J Clin Oncol; 1992 Feb; 15(1):7-11. PubMed ID: 1550083 [TBL] [Abstract][Full Text] [Related]
14. Chemotherapy, early surgical reassessment, and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: results of a gynecologic oncology group study. Randall ME; Barrett RJ; Spirtos NM; Chalas E; Homesley HD; Lentz SL; Hanna M Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):139-47. PubMed ID: 12118543 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. Omura GA; Brady MF; Homesley HD; Yordan E; Major FJ; Buchsbaum HJ; Park RC J Clin Oncol; 1991 Jul; 9(7):1138-50. PubMed ID: 1904477 [TBL] [Abstract][Full Text] [Related]
16. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy. Petit T; Velten M; d'Hombres A; Marchal C; Montbarbon X; Mornex F; Quetin P; Gérard JP; Romestaing P; Carrie C Gynecol Oncol; 2007 Jan; 104(1):104-8. PubMed ID: 16987544 [TBL] [Abstract][Full Text] [Related]
17. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Hakes TB; Chalas E; Hoskins WJ; Jones WB; Markman M; Rubin SC; Chapman D; Almadrones L; Lewis JL Gynecol Oncol; 1992 Jun; 45(3):284-9. PubMed ID: 1612505 [TBL] [Abstract][Full Text] [Related]
18. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983 [TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal cisplatin chemotherapy versus abdominopelvic irradiation in ovarian carcinoma patients after second look laparotomy. A reassessment based on mature data. Ben-Baruch G; Menczer J; Feldman B; Rizel S; Brenner H Eur J Gynaecol Oncol; 1994; 15(4):272-6. PubMed ID: 7957334 [TBL] [Abstract][Full Text] [Related]